Denny Lanfear, Coherus BioSciences CEO
June 16, 2023 07:34 AM EDTUpdated 08:48 AM
People
Deals

Co­herus to buy Sur­face On­col­o­gy in stock deal val­ued at $65M

Kyle LaHucik

Senior Reporter

Co­herus Bio­Sciences is mak­ing a small stock-for-stock trans­ac­tion to shore up its im­muno-on­col­o­gy pipeline in an ac­qui­si­tion of Sur­face On­col­o­gy that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times